GLP-1-derived therapies and risk of sarcopenia: myth or reality?
Level 5 - mechanism / opinion, no new human data
Narrative review / expert opinion without systematic review methodology reported in abstract
PubMed 41851969 · doi:10.1080/14740338.2026.2640980
What was done
This review examined human studies evaluating the effects of glucagon-like peptide-1 (GLP-1)-based therapies on skeletal muscle mass, muscle strength and function, and muscle structure and quality in individuals treated for obesity and/or type 2 diabetes.
What was found
The abstract provides no numerical data. It notes mixed findings across published studies: while some reports emphasized skeletal muscle mass loss during GLP-1 therapy, recent evidence indicates that this loss is not disproportionate relative to other weight-loss interventions. Furthermore, reports indicate potential improvements in muscle quality via reduced intramuscular fat infiltration (myosteatosis), with preserved muscle strength and physical performance.
Why it matters
As GLP-1 receptor agonists become foundational treatments for obesity and diabetes, clarifying whether associated lean mass loss leads to functional sarcopenia is essential for evaluating long-term safety, especially in aging populations.
Limits
This is a narrative review rather than a systematic review or meta-analysis. The abstract cites a general scarcity of human trials that rigorously assess muscle quality and function, and notes that data are particularly lacking for high-risk groups such as frail or older patients.
Cited by
- contradicts Ozempic face is caused by GLP-1 receptor agonists directly inducing sarcopenia in facial muscles.